Form 8-K - Current report:
SEC Accession No. 0001104659-24-056664
Filing Date
2024-05-03
Accepted
2024-05-03 07:01:29
Documents
15
Period of Report
2024-05-03
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2413422d1_8k.htm   iXBRL 8-K 27199
2 EXHIBIT 99.1 tm2413422d1_ex99-1.htm EX-99.1 14317
6 GRAPHIC tm2413422d1_ex99-1img001.jpg GRAPHIC 7932
  Complete submission text file 0001104659-24-056664.txt   234247

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeon-20240503.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeon-20240503_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeon-20240503_pre.xml EX-101.PRE 22393
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2413422d1_8k_htm.xml XML 3799
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 24910760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)